Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Polivy
Discover more about POLIVY for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Gazyvaro
Discover more about where Gazyvaro is indicated for the treatment of patients with CLL and FL.
Expert discussions
Listen to insights on the most up-to-date haematology data, as discussed by experts in the field.
Congress highlights
Learn more about the key data highlights presented at congresses and how they could impact UK clinical practice.
For full details, please refer to the Gazyvaro® or Polivy® Summary of Product Characteristics.
FL, follicular lymphoma; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma.
M-GB-00004807
Date of preparation: September 2021